+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 12Years - 39Years
All Genders
ID04616560

A Study of Trastuzumab Deruxtecan DS-8201a in Children, Adolescents, and Young Adults with Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Led by National Cancer Institute (NCI) · Updated on 2026-10-28

55

Participants Needed

32

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating trastuzumab deruxtecan DS-8201a, an antibody-drug conjugate, for treating patients with osteosarcoma, Wilms tumor WT, or desmoplastic small round cell tumor DSRCT that is newly diagnosed, recurrent, or refractory to previous treatments. This phase III trial aims to estimate the maximum tolerated dose and antitumor activity of DS-8201a, focusing on children and young adults with these cancers. The study also explores safety, pharmacokinetics, and potential biomarkers predicting response. Participants receive trastuzumab deruxtecan intravenously over 30 to 90 minutes on day 1, repeated every 21 days for up to 35 cycles unless disease progresses or unacceptable toxicity occurs. Throughout the study, patients undergo imaging tests such as CT and MRI, heart function assessments via echocardiography or MUGA scans, and blood sample collections. After completing treatment, there is a follow-up visit six months later. During the trial, researchers monitor adverse events, tumor response, progression, and survival outcomes. Blood tests and imaging help assess treatment effects and safety. The primary outcome includes determining the dose tolerated by children aged 2 to less than 12 years. Secondary outcomes cover safety and response rates up to one year. Participants are observed closely with scheduled assessments to support these measurements over the study period.

CONDITIONS

Brief Title

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here